REN and Hypertension: It is possible that the use of renin–angiotensin–aldosterone system inhibitor (RAASI) reflects a reduction in mortality, and the low RAASI use in the early mortality group (36.1% in the early mortality group vs. 51.6% in the non-early mortality group) was associated with a low prevalence of hypertension during the retrospective data collection process28–30.